Foi realizada uma busca nas plataformas on-line Ebsco, SciELO, PubMed, Medline Bireme, Lilacs e New England Journal of Medicine. Foram selecionadas publicações de 2010 a 2018 referentes a artigos que continham grupos controle, que testaram a validade de Dupilumabe e verificaram a resposta dos pacientes por meio de testes controlados. Para a busca desses artigos, foram utilizadas as seguintes palavras-chave: “Dupilumab”, “asthma”, “Bronchial Asthma” and “Asthma, Bronchial”. E o correspondente em português: “asma”, “Asma brônquica” and “Asma brônquica”. Os critérios de exclusão, revisões de literatura, notícias, artigos sem grupos de controle, artigos sobre diferentes assuntos, estudos de Dupilumabe sobre outras doenças, artigos sobre asma sem uso de Dupilumabe e artigos repetidos em plataformas de busca foram descartados.

RESULTADOS

A literatura aponta que a medicação apresenta boa resposta no tratamento da asma moderada a grave e auxilia na melhora da função pulmonar, além de resultar em poucos efeitos colaterais. Apresenta boa eficácia, segurança e tolerância pelos pacientes.

CONCLUSÕES

Dupilumabe é promissor para o tratamento da asma em que a terapia convencional se revela insuficiente. Maiores estudos adicionais são necessários para confirmar a segurança e a eficácia em longo prazo.

Dupilumabe; Asma; Broncopatias; Antiasmáticos

Database	First Criterion	Second Criterion
	Total Included	Total Included
EBSCO	20 0	0 0
SCIELO	0 0	0 0
MEDLINE	64 1	1 1
LILACS	1 1	1 0
PUBMED	67 1	1 1
NEW ENGLAND J	13 3	3 3
Total	165 6	6 5

Reference	Date of publication	Number of individuals and age group	Medication dosage	Outcome
Busse et al.¹	May, 2018	1902 patients aged ≥12 years were randomized in a 2: 2: 2: 1 ratio. three groups. Duration of 52 weeks	Group 1: 634 patients. 300 mg of Dupilumab every two weeks. Group 2: 364 patients, 200 mg of Dupilumab every two weeks. Group 3: 317 patients, placebo.	Dupilumab had an excellent response to moderate to severe uncontrolled asthma, provides improvement in respiratory function and control of asthma. Severe exercise reduction and improved quality of life
Castro et al.²	June, 2018	1902 patients aged ≥12 years with uncontrolled asthma divided in 2: 2: 1 ratio. Three groups. Duration of 52 weeks.	Group 1: 300 mg of Dupimulab every two weeks. Group 2: 200 mg of Dupimulab every two weeks. Group 3: Placebo.	Patients who received Dupimulab had a significant improvement in lung function, asthma control, and minor exacerbations of severe asthma compared to the placebo group.
Rabe et al.³	June, 2018	210 patients aged ≥ 12 years. Two groups. Duration of 24 weeks.	Group 1: 200 mg of Dupimulab every two weeks. Group 2: Placebo.	The use of Dupimulab decreases the exacerbation of severe asthma and improved FEV1.
Wenzel et al.⁴	April, 2016	769 patients aged≥ 18 years, of whom 611 were in the Dupimulab and 158 in the placebo group. Five groups with a ratio of 1: 1: 1: 1: 1. Duration of 24 + 16 weeks.	Group 1: 200 mg of Dupimulab every 4 weeks. Group 2: Dupimulab 300 mg every 4 weeks. Group 3: 200 mg of Dupimulab every 2 weeks. Group 4: 300 mg of Dupimulab every 2 weeks. Group 5: Placebo.	Groups using Dupilumab, except for 200 mg every 4 weeks, showed a significant improvement in FEV1, reduced asthma exacerbation and eosenophilia. The best results were found in the 300 mg Dupilumab group every 2 weeks.
Wenzel et al.⁵	June, 2013	104 patients, divided into two, each with 52 patients. One group received Dupilumab and the other placebo. Duration of 12 weeks.	Group 1: 300 mg Dupilumab weekly. Group 2: Placebo.	The use of Dupilumab reduced asthma exacerbations and levels of inflammatory markers associated with Th2, in addition to showing improvement in lung function.

Associação Médica Brasileira R. São Carlos do Pinhal, 324, 01333-903 São Paulo SP - Brazil, Tel: +55 11 3178-6800, Fax: +55 11 3178-6816 - São Paulo - SP - Brazil
E-mail: ramb@amb.org.br

Acompanhe os números deste periódico no seu leitor de RSS

[1] CORRESPONDING AUTHOR: Leonardo Saraiva BR 285 – Passo Fundo – Rio Grande do Sul – Brasil – 99052-900 – Tel:+55 54 33168384 E-mail: leo77saraiva@hotmail.com